ActiveOps Plc (LON:AOM – Get Free Report)’s stock price reached a new 52-week low during trading on Monday. The company traded as low as GBX 90 and last traded at GBX 90.84, with a volume of 58,786 shares. The stock had previously closed at GBX 92.50.
Analyst Ratings Changes
Separately, Canaccord Genuity Group cut their price objective on shares of ActiveOps from GBX 355 to GBX 300 and set a “buy” rating for the company in a report on Monday, October 12th. One investment analyst has rated the stock with a Buy rating. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of GBX 300.
View Our Latest Stock Report on AOM
ActiveOps Trading Down 1.8%
The firm has a market capitalization of £65.02 million, a P/E ratio of -28.13 and a beta of 0.80. The company has a quick ratio of 1.20, a current ratio of 0.68 and a debt-to-equity ratio of 1.49. The firm has a 50 day moving average of GBX 171.41 and a 200-day moving average of GBX 213.20.
Insiders Place Their Bets
In other news, insider Emma Salthouse sold 25,269 shares of the company’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of GBX 190, for a total transaction of £48,011.10. 13.06% of the stock is owned by corporate insiders.
About ActiveOps
ActiveOps’ offerings provide predictive and prescriptive insight to help service operations make better decisions – faster. The Company’s AI-powered SaaS solutions are underpinned by 15+ years of operational data and its AOM methodology that’s proven to drive cross department decision-making.
With Decision Intelligence, ActiveOps’ customers deliver MORE – release 20%+ capacity within the first 12 months and boost productivity by 30%+ leading to MORE business impact. Customer turnaround times are improved substantially, costs are reduced, SLAs are met, and employees are happier and more engaged.
Featured Stories
- Five stocks we like better than ActiveOps
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for ActiveOps Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ActiveOps and related companies with MarketBeat.com's FREE daily email newsletter.
